Showing 801 - 820 results of 40,970 for search '(( 50 ((teer decrease) OR (mean decrease)) ) OR ( 16 ((nn decrease) OR (a decrease)) ))', query time: 0.84s Refine Results
  1. 801
  2. 802
  3. 803
  4. 804
  5. 805
  6. 806
  7. 807
  8. 808
  9. 809
  10. 810

    Comparison of choroidal measurements in vitreoretinal lymphoma (VRL) eyes and their fellow eyes. by Rae-Young Kim (11747549)

    Published 2021
    “…Mean SFCT after maintenance treatment was 255.50±80.61, which was not significantly different from that in remission (p = 0.690). …”
  11. 811

    Image 4_The immunomodulatory and antitumor properties of the bacterial metalloprotease Oligopeptidase A are mediated by TLR4/MyD88/TRIF and MAPK signaling pathways.tiff by Priscila Silva (556743)

    Published 2025
    “…Our previous work showed that the bacterial metalloprotease arazyme has a strong in vivo antimetastatic effect in the B16F10-Nex2 murine melanoma model. …”
  12. 812

    Image 2_The immunomodulatory and antitumor properties of the bacterial metalloprotease Oligopeptidase A are mediated by TLR4/MyD88/TRIF and MAPK signaling pathways.tiff by Priscila Silva (556743)

    Published 2025
    “…Our previous work showed that the bacterial metalloprotease arazyme has a strong in vivo antimetastatic effect in the B16F10-Nex2 murine melanoma model. …”
  13. 813

    Image 1_The immunomodulatory and antitumor properties of the bacterial metalloprotease Oligopeptidase A are mediated by TLR4/MyD88/TRIF and MAPK signaling pathways.tif by Priscila Silva (556743)

    Published 2025
    “…Our previous work showed that the bacterial metalloprotease arazyme has a strong in vivo antimetastatic effect in the B16F10-Nex2 murine melanoma model. …”
  14. 814

    Image 3_The immunomodulatory and antitumor properties of the bacterial metalloprotease Oligopeptidase A are mediated by TLR4/MyD88/TRIF and MAPK signaling pathways.tiff by Priscila Silva (556743)

    Published 2025
    “…Our previous work showed that the bacterial metalloprotease arazyme has a strong in vivo antimetastatic effect in the B16F10-Nex2 murine melanoma model. …”
  15. 815
  16. 816
  17. 817
  18. 818
  19. 819

    A shift towards CD16+ monocyte subsets in kidney transplant recipients. by Elly J. F. Vereyken (438616)

    Published 2013
    “…<p>Representative FACS-plots of CD14/CD16 staining are shown: (A) healthy controls, (B) recipient at the time of Tx, (C) recipient 3 months post-Tx and (D) 6 months post-Tx. …”
  20. 820